/Pipeline
Pipeline2018-12-20T02:07:55+00:00

Strong Patents Granted And Deep Pipeline Of Ophthalmic Drug Candidates

We have shown that CBT-001 can suppress cornea neovascularization and regress grafted human pterygium tissue in animal models. Our studies have enabled us to globally file patent for a novel method of use of multikinase inhibitor class of compounds for pterygium treatment. We already received two patent (US 9987223 and US 9980901) issue notifications from USPTO in May 2018. US 9987223 is for multikinase inhibitors to treat pterygium. Compositions and methods for inducing pterygium regression from visual axis/central cornea, stabilizing pterygium, treating hyperemia and symptoms in pterygium patients, and treating pterygium recurrence following pterygiectomy are disclosed. The methods include administration of a multikinase inhibitor, an antimetabolite or a combination thereof to patients in need thereof. US 9980901 is for multikinase inhibitors and antimetabolites combo to treat pterygium. Compositions and methods for inducing pterygium regression from visual axis/central cornea, stabilizing pterygium, treating hyperemia and symptoms in pterygium patients, and treating pterygium recurrence following pterygiectomy are disclosed. The methods include administration of a multikinase inhibitor, an antimetabolite or a combination thereof to patients in need thereof.